公司资料
Biohaven 股价、新闻与催化剂
- 股票代码:
- BHVN
- 交易所:
- NYSE
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
13.14 USD (-1.57%)
收盘价
最后更新: 2026年10月1日
1.53B USD
市值
股价为何变动
截至 2026年10月1日，BHVN 下跌 1.57%，收于 $13.14。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Biohaven is a biopharmaceutical company focused on neuroscience, immunology, and rare disease. Its business combines commercial assets with a pipeline aimed at multiple specialty indications.
所在地与行业分类
Biohaven is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a strong neuroscience footprint.
商业模式特征
The company depends on product sales, launch execution, and pipeline expansion across CNS and immune-mediated disease. Investors watch revenue, development milestones, and strategic execution.
生物医药行业定位
Biohaven occupies a premium specialty-biopharma niche within biotech. It has both commercial grounding and catalyst sensitivity, which keeps the stock lively.
未来催化剂
- Biohaven’s catalysts are its neuroscience pipeline, especially migraine and related CNS programs, plus any update that broadens the commercial story. The company remains one of the cleaner CNS growth names if execution holds.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。